Category: chronic diseases

The Role of Inhaled Long-Acting Beta-2 Agonists in the Management of Asthma. Clinical Use of LABAs

The LABAs are approved for chronic maintenance therapy of asthma, chronic obstructive pul¬monary disease and exercise-induced bronchospasm (EIB). Numerous trials have demonstrated the superiority of maintenance therapy with an inhaled LABA (administered twice daily) to maintenance therapy with an inhaled short-acting beta-2 agonist (administered four times daily). Therapy with LABAs improves lung function, bronchial hyperre-sponsiveness […]

Read more

Clinical Pharmacology of the LABAs

LABAs differ from short-acting inhaled beta-2 agonists principally in having large side chains, increasing their lipophilicity. The greater water solubility of short-acting inhaled beta-2 agonists, such as albuterol, leads them to diffuse away from the beta-2-adrenergic receptors, limiting their duration of action. The greater lipophilicity of formoterol and salmeterol facilitates their partitioning and retention in […]

Read more

Management of Asthma

National and international guidelines for the management of concur on the goals of therapy (Table 1)  and on the components of the care necessary to achieve them (Table 2). The components of care involve eliminating or avoiding disease exacerbating factors, monitoring, education and pharmacotherapy. The guidelines agree that pharmacotherapy should consist of the treatment that can […]

Read more

The Role of Inhaled Long-Acting Beta-2 Agonists in the Management of Asthma

The role of inhaled beta-2 agonists in the management of asthma has changed significantly over the last several years. This review outlines the most recent understanding of the pathophysiology of asthma and the studies that define the roles lhat both short- and long-acting beta-2 agonists play in therapy for this disease. A concentration on the […]

Read more

CHRONIC FATIGUE SYNDROME – Pharmacologic Therapy

No treatment has been proved to benefit patients with CFS in large randomized controlled trials that have been replicated by other investigators in other populations of patients. Moreover, without a better understanding of the pathogenesis of CFS, it is unlikely that definitive treatment will be identified. Indeed, the pharmacologic treatment of CFS primarily involves the […]

Read more

MANAGEMENT OF CHRONIC FATIGUE SYNDROME

Nonpharmacologic Management Management of the patient with CFS requires more than pharmacotherapy. First, the clinician must make a personal judgment as to whether patients are accurately relating their symptoms -both those that they admit to and those that they deny. CFS is an illness defined only by symptoms. Thus, an occasional patient seeking secondary gain […]

Read more